Which human papillomavirus vaccine and vaccination strategy for national programs?
Open Access
- 1 September 2018
- journal article
- editorial
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 97 (9) , 1049-1050
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Gender‐neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)International Journal of Cancer, 2018
- Vaccination protects against invasive HPV‐associated cancersInternational Journal of Cancer, 2017
- Worldwide burden of cancer attributable to HPV by site, country and HPV typeInternational Journal of Cancer, 2017
- Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013Emerging Infectious Diseases, 2016
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in WomenNew England Journal of Medicine, 2015
- A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old GirlsPLOS ONE, 2013
- Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young womenInternational Journal of Cancer, 2011
- Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine, 2007